Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
JAMA network open - 4(2021), 12 vom: 01. Dez., Seite e2136697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McKay, Kyla A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1001/jamanetworkopen.2021.36697 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333882806 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333882806 | ||
| 003 | DE-627 | ||
| 005 | 20240404233325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamanetworkopen.2021.36697 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM333882806 | ||
| 035 | |a (NLM)34851401 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a McKay, Kyla A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Piehl, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Englund, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a He, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Langer-Gould, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Hillert, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Frisell, Thomas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA network open |d 2018 |g 4(2021), 12 vom: 01. Dez., Seite e2136697 |w (DE-627)NLM289300517 |x 2574-3805 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2021 |g number:12 |g day:01 |g month:12 |g pages:e2136697 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jamanetworkopen.2021.36697 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2021 |e 12 |b 01 |c 12 |h e2136697 | ||